Callahan Advisors LLC Purchases 2,343 Shares of Johnson & Johnson (NYSE:JNJ)

Callahan Advisors LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 125,052 shares of the company's stock after purchasing an additional 2,343 shares during the period. Johnson & Johnson comprises 2.0% of Callahan Advisors LLC's holdings, making the stock its 11th largest position. Callahan Advisors LLC's holdings in Johnson & Johnson were worth $20,739,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. WealthTrak Capital Management LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth about $26,000. Mountain Hill Investment Partners Corp. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth about $29,000. Conquis Financial LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth about $33,000. Bernard Wealth Management Corp. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth about $36,000. Finally, Runnymede Capital Advisors Inc. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth about $38,000. Institutional investors own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of recent research reports. Morgan Stanley restated an "underperform" rating on shares of Johnson & Johnson in a research note on Thursday. Barclays cut their target price on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Thursday, June 5th. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Eleven analysts have rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $171.00.

Johnson & Johnson Stock Down 0.5%

Johnson & Johnson stock opened at $156.87 on Friday. The stock has a market cap of $377.44 billion, a P/E ratio of 17.45, a P/E/G ratio of 2.14 and a beta of 0.41. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company's 50-day moving average price is $153.75 and its two-hundred day moving average price is $154.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The firm had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, May 27th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.31%. Johnson & Johnson's dividend payout ratio (DPR) is currently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.